AADC Gene Therapy for Parkinson`s Disease
... a gene, AADC (aromatic amino acid decarboxylase) into the brains of people with moderately advanced Parkinson’s disease. In this study, the AADC gene will be delivered to a specific area of the brain and it may increase dopamine production in the brain. It is the third study of its kind. The study w ...
... a gene, AADC (aromatic amino acid decarboxylase) into the brains of people with moderately advanced Parkinson’s disease. In this study, the AADC gene will be delivered to a specific area of the brain and it may increase dopamine production in the brain. It is the third study of its kind. The study w ...
Corporate Presentation
... • Proprietary reformulation of Squalamine into a topical eye drop for increased patient ease of use and a consistent delivery of therapeutic concentrations. • Current approved therapies are delivered via intravitreal injection directly into the eye every month or two. Cost effective manufacture • IV ...
... • Proprietary reformulation of Squalamine into a topical eye drop for increased patient ease of use and a consistent delivery of therapeutic concentrations. • Current approved therapies are delivered via intravitreal injection directly into the eye every month or two. Cost effective manufacture • IV ...
Management of Pelvic Inflammatory Disease
... Women with HIV may have more severe symptoms associated with PID but respond well to antibiotic therapy, although parenteral regimens may be required [5-8]. There is no evidence of the superiority of any one of the recommended regimens over the others. Therefore patients known to be allergic to ...
... Women with HIV may have more severe symptoms associated with PID but respond well to antibiotic therapy, although parenteral regimens may be required [5-8]. There is no evidence of the superiority of any one of the recommended regimens over the others. Therefore patients known to be allergic to ...
to the PDF file. - International Multiple Sclerosis
... progression of MS. The goal of the Intrathecal Methotrexate Biomarker Study is to discover cerebrospinal fluid (CSF) biomarkers that can identify which patients are responding to the methotrexate treatment. Patients enrolled in the study will have CSF samples taken before initiation of the treatment ...
... progression of MS. The goal of the Intrathecal Methotrexate Biomarker Study is to discover cerebrospinal fluid (CSF) biomarkers that can identify which patients are responding to the methotrexate treatment. Patients enrolled in the study will have CSF samples taken before initiation of the treatment ...
Allergy - Immunology - University of Arizona Department of Pediatrics
... A. Create a strategy to investigate whether the following presenting signs and symptoms are caused by an allergic process or immunologic dysfunction, and determine if the patient should be treated or referred: 1. Cough 2. Wheezing 3. Skin rash 4. Recurrent pneumonia 5. Recurrent skin infections 6. R ...
... A. Create a strategy to investigate whether the following presenting signs and symptoms are caused by an allergic process or immunologic dysfunction, and determine if the patient should be treated or referred: 1. Cough 2. Wheezing 3. Skin rash 4. Recurrent pneumonia 5. Recurrent skin infections 6. R ...
What is the future of targeted therapy in Open Access
... molecules) determines several important features, such as route of administration, half-life, localization of the target, manufacturing standards, and so on (Table 1). Therefore, despite their rather different therapeutic targets, these biologic agents are considered a unique group of therapeutics i ...
... molecules) determines several important features, such as route of administration, half-life, localization of the target, manufacturing standards, and so on (Table 1). Therefore, despite their rather different therapeutic targets, these biologic agents are considered a unique group of therapeutics i ...
Acute viral neurological diseases
... Isolation of the virus in tissue culture, followed by identification of the isolated virus. MRI (magnetic resonance imaging) provides high quality picture of the brain, useful in the identification of edema, necrosis and hemorrhage. ...
... Isolation of the virus in tissue culture, followed by identification of the isolated virus. MRI (magnetic resonance imaging) provides high quality picture of the brain, useful in the identification of edema, necrosis and hemorrhage. ...
The Use of Antidepressants in the Treatment of Irritable Bowel
... recovery of more normal brain-gut function, possibly by helping the brain send down signals to block incoming pain impulses, a natural response. Much like treating diabetes with the insulin that is missing, antidepressants may help recover the brain's ability to respond to pain signals properly. Cer ...
... recovery of more normal brain-gut function, possibly by helping the brain send down signals to block incoming pain impulses, a natural response. Much like treating diabetes with the insulin that is missing, antidepressants may help recover the brain's ability to respond to pain signals properly. Cer ...
DRUG NAME: Ruxolitinib
... in women. Drugs should be given only if the potential benefit justifies the potential risk to the fetus. Ruxolitinib is associated with maternal toxicity, embryolethality, and fetotoxicity in animal studies.3 Breastfeeding is not recommended due to the potential secretion into breast milk.3 ...
... in women. Drugs should be given only if the potential benefit justifies the potential risk to the fetus. Ruxolitinib is associated with maternal toxicity, embryolethality, and fetotoxicity in animal studies.3 Breastfeeding is not recommended due to the potential secretion into breast milk.3 ...
DRUGSCAN
... months later characteristically responds better to second line therapies and indeed to retreatment with cisplatin. Researchers at a Dutch institution have investigated the worth of intensified cisplatin therapy in conjunction with a synergistic agent (oral etoposide) against relapsed ovarian cancer. ...
... months later characteristically responds better to second line therapies and indeed to retreatment with cisplatin. Researchers at a Dutch institution have investigated the worth of intensified cisplatin therapy in conjunction with a synergistic agent (oral etoposide) against relapsed ovarian cancer. ...
$doc.title
... act with possible complications and should not be performed for the evaluation of tolerance during MTX treatment. The survey should be oriented by biologial tests (PIIINP, fibrotest®) combined if needed with fibroscan® test. ...
... act with possible complications and should not be performed for the evaluation of tolerance during MTX treatment. The survey should be oriented by biologial tests (PIIINP, fibrotest®) combined if needed with fibroscan® test. ...
Kopie_von_Kneipp_Therapy_-Translation 4
... the patient and, in many cases, with partial self financing of the medial costs. The patient takes responsibility, in conjunction with the treating physician, for the decision as to which therapy is best suited for him. The appraisal of subjective parameters such as pain, vegetative dysfunction and ...
... the patient and, in many cases, with partial self financing of the medial costs. The patient takes responsibility, in conjunction with the treating physician, for the decision as to which therapy is best suited for him. The appraisal of subjective parameters such as pain, vegetative dysfunction and ...
Timoptol XE
... TIMOPTOL-XE reduces elevated and normal intraocular pressure whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss. The higher the intraocular pressure, the greater the likelihood of glaucomatous visual fie ...
... TIMOPTOL-XE reduces elevated and normal intraocular pressure whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss. The higher the intraocular pressure, the greater the likelihood of glaucomatous visual fie ...
cioms form suspect adverse reaction report
... The investigator explained the events dysarthria, hypoventilation tetany and ataxia could be (known) side effects of Oxaliplatin. The combination of all symptoms at the same point in time was the essential reason for hospitalization. The patient did not experience anxiety. The investigator clarified ...
... The investigator explained the events dysarthria, hypoventilation tetany and ataxia could be (known) side effects of Oxaliplatin. The combination of all symptoms at the same point in time was the essential reason for hospitalization. The patient did not experience anxiety. The investigator clarified ...
Spasticity
... Department of Physical Medicine and Rehabilitation Johns Hopkins University School of Medicine ...
... Department of Physical Medicine and Rehabilitation Johns Hopkins University School of Medicine ...
GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation
... which is the first evidence-based definition: ‘Premature ejaculation is a male sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations ...
... which is the first evidence-based definition: ‘Premature ejaculation is a male sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations ...
Suggested Framework for Medical Management of Persons
... contamination who is afebrile and has signs and symptoms consistent with a minor gastrointestinal illness, such vomiting or diarrhea, could be managed expectantly (as for an exposed, asymptomatic person); this is a reasonable approach to limit low-yield testing and support judicious use of antimicro ...
... contamination who is afebrile and has signs and symptoms consistent with a minor gastrointestinal illness, such vomiting or diarrhea, could be managed expectantly (as for an exposed, asymptomatic person); this is a reasonable approach to limit low-yield testing and support judicious use of antimicro ...
First-in-Human Phase I administration of YS110, a humanized
... • PK data demonstrated shorter half‐life than expected which led to modifying the dosing schedule from two weeks to one week. • Encouraging safety profile has been obtained • Encouraging anti‐tumor efficacy remains to be confirmed at higher dose levels and extension cohorts ...
... • PK data demonstrated shorter half‐life than expected which led to modifying the dosing schedule from two weeks to one week. • Encouraging safety profile has been obtained • Encouraging anti‐tumor efficacy remains to be confirmed at higher dose levels and extension cohorts ...
Projected Cost Savings of Introducing fecal
... (ICER) of anidulafungin (200 mg on the first day, followed by 100 mg daily) compared to amphotericin B deoxycholate (0.7-1.0 mg daily); amphotericin B liposomal (5.0 mg/ kg daily); caspofungin (70 mg on the first day followed by 50 mg daily) and fluconazole (800 mg on the first day followed by 400 m ...
... (ICER) of anidulafungin (200 mg on the first day, followed by 100 mg daily) compared to amphotericin B deoxycholate (0.7-1.0 mg daily); amphotericin B liposomal (5.0 mg/ kg daily); caspofungin (70 mg on the first day followed by 50 mg daily) and fluconazole (800 mg on the first day followed by 400 m ...
Dimethyl fumarate and progressive multifocal
... used in combination with other immunosuppressive medications (eg, cyclophosphamide, leflunomide, methotrexate). Many of the patients had an underlying hematologic malignancy or collagen vascular disease [3]. There is no specific treatment for PML. The main approach is restoring the host adaptive imm ...
... used in combination with other immunosuppressive medications (eg, cyclophosphamide, leflunomide, methotrexate). Many of the patients had an underlying hematologic malignancy or collagen vascular disease [3]. There is no specific treatment for PML. The main approach is restoring the host adaptive imm ...
Expert Committee for Consensus on Management of BPH -
... awareness that the individual patient will always be managed according to an individual need and not towards a guide. Having underlined that, this paper is meant to address the need for NonUrologists to appreciate the new developments as perceived by the Urological Community. This latter point is es ...
... awareness that the individual patient will always be managed according to an individual need and not towards a guide. Having underlined that, this paper is meant to address the need for NonUrologists to appreciate the new developments as perceived by the Urological Community. This latter point is es ...
Immunosuppressive therapy and sarcoidosis
... Not many reliable prediction criteria on who will progress to more active disease Mixed data on whether treatment early leads to remission vs. observation in patients with stage II or III sarcoidosis with limited symptoms Some symptoms may actually be made worse by treatment with immune suppress ...
... Not many reliable prediction criteria on who will progress to more active disease Mixed data on whether treatment early leads to remission vs. observation in patients with stage II or III sarcoidosis with limited symptoms Some symptoms may actually be made worse by treatment with immune suppress ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.